A Physiologically Based Pharmacokinetic Model to Predict Potential Drug–Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor

Acumapimod, an investigational oral p38 mitogen‐activated protein kinase inhibitor for treatment during severe acute exacerbations of chronic obstructive pulmonary disease, is metabolized primarily by cytochrome P450 3A4 (CYP3A4) and is a P‐glycoprotein (P‐gp) substrate. Concerns about drug–drug int...

Descripción completa

Detalles Bibliográficos
Autores principales: Agyemang, Alex, Farrell, Colm, Moore, William, Parkin, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825188/
https://www.ncbi.nlm.nih.gov/pubmed/33107218
http://dx.doi.org/10.1002/psp4.12565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825188/
https://www.ncbi.nlm.nih.gov/pubmed/33107218
http://dx.doi.org/10.1002/psp4.12565

Ejemplares similares